Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BMRN 
Biomarin Pharmaceutical Inc (BMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: BMRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $89.36
1 Year Target Price $89.36
| 16 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.43B USD | Price to earnings Ratio 20.19 | 1Y Target Price 89.36 |
Price to earnings Ratio 20.19 | 1Y Target Price 89.36 | ||
Volume (30-day avg) 29 | Beta 0.3 | 52 Weeks Range 50.76 - 73.51 | Updated Date 12/4/2025 |
52 Weeks Range 50.76 - 73.51 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.82% | Operating Margin (TTM) -6.02% |
Management Effectiveness
Return on Assets (TTM) 6.15% | Return on Equity (TTM) 9.07% |
Valuation
Trailing PE 20.19 | Forward PE 11.19 | Enterprise Value 9696533206 | Price to Sales(TTM) 3.37 |
Enterprise Value 9696533206 | Price to Sales(TTM) 3.37 | ||
Enterprise Value to Revenue 3.13 | Enterprise Value to EBITDA 12.55 | Shares Outstanding 192114344 | Shares Floating 190444870 |
Shares Outstanding 192114344 | Shares Floating 190444870 | ||
Percent Insiders 0.78 | Percent Institutions 98.06 |
Upturn AI SWOT
Biomarin Pharmaceutical Inc
Company Overview
History and Background
BioMarin Pharmaceutical Inc. was founded in 1997. It focuses on developing and commercializing therapies for serious and life-threatening rare genetic diseases and other genetic conditions. They have several FDA-approved therapies.
Core Business Areas
- Commercial Operations: Focuses on the sales, marketing, and distribution of BioMarin's approved therapies worldwide.
- Research and Development: Dedicated to discovering, developing, and manufacturing innovative therapies for genetic diseases.
- Manufacturing: Responsible for the production and supply of BioMarin's pharmaceutical products.
Leadership and Structure
The leadership team includes Alexander J. Denner as CEO, and the company is structured into various departments including R&D, Commercial, and Manufacturing.
Top Products and Market Share
Key Offerings
- Vimizim: Vimizim (elosulfase alfa) is an enzyme replacement therapy for Morquio A syndrome (MPS IVA). Market share data is not readily available, but it's a dominant therapy in the MPS IVA market. Competitors are limited due to the specificity of the therapy.
- Naglazyme: Naglazyme (galsulfase) is an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI). Market share data is not readily available. Competitors are limited due to the specificity of the therapy.
- Brineura: Brineura (cerliponase alfa) is an enzyme replacement therapy for CLN2 disease, a form of Batten disease. Market share data is not readily available. Competitors are limited due to the specificity of the therapy.
- Voxzogo: Voxzogo (vosoritide) is a therapy for achondroplasia, the most common form of dwarfism. The global market size was estimated at $29.8 million in 2021 and projected to reach $1.6 billion by 2031. Market share is growing. Competitors include Pfizer's achondroplasia program.
- Kuvan: Kuvan (sapropterin dihydrochloride) treats phenylketonuria (PKU). Its market share has decreased due to generic competition. Competitors include other PKU management strategies like dietary management.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The rare disease segment is growing, driven by increased awareness and unmet medical needs.
Positioning
BioMarin is a leader in developing therapies for rare genetic diseases, with a strong focus on enzyme replacement and gene therapies. Their competitive advantage lies in their expertise in these areas and their established pipeline of innovative products.
Total Addressable Market (TAM)
The total addressable market (TAM) for rare genetic disease treatments is substantial and growing, estimated to be in the tens of billions of dollars globally. BioMarin is positioned to capture a significant share of this market with its diverse portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Strong focus on rare genetic diseases
- Established pipeline of innovative products
- Expertise in enzyme replacement and gene therapies
- Experienced management team
- FDA approved therapies for many genetic disease.
Weaknesses
- High R&D costs
- Reliance on a limited number of products
- Risk associated with clinical trial outcomes
- Generic competition affecting existing products
- Dependence on orphan drug designation and pricing.
Opportunities
- Expanding into new rare disease areas
- Developing gene therapies for previously untreatable conditions
- Partnering with other pharmaceutical companies
- Acquiring smaller biotech companies with promising pipelines
- Geographic expansion into emerging markets.
Threats
- Increased competition from other pharmaceutical companies
- Regulatory challenges and changes in drug approval processes
- Pricing pressures from healthcare providers and payers
- Unsuccessful clinical trials
- Patent expirations and generic competition.
Competitors and Market Share
Key Competitors
- SGEN
- GILD
- REGN
Competitive Landscape
BioMarin has a strong position in the rare disease market, but faces competition from larger pharmaceutical companies with greater resources. BioMarin's competitive advantage lies in its focus on rare genetic diseases and its expertise in enzyme replacement and gene therapies.
Major Acquisitions
Prosensa
- Year: 2014
- Acquisition Price (USD millions): 840
- Strategic Rationale: Expanded BioMarin's pipeline in Duchenne muscular dystrophy treatment.
Growth Trajectory and Initiatives
Historical Growth: BioMarin has experienced significant growth in revenue over the past decade, driven by the approval and commercialization of new therapies.
Future Projections: Analyst estimates for future growth are available from financial data providers.
Recent Initiatives: Recent initiatives include focusing on the development of gene therapies, expanding into new geographic markets, and investing in research and development.
Summary
BioMarin is a key player in the rare disease treatment market with approved therapies and gene therapy developments. Its focus on rare diseases and innovative treatments creates a strong pipeline. Competition from bigger companies and maintaining strong research pipeline are key for future success. While the company does not pay dividends, its growth potential appeals to investors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Analyst Reports
- Industry Publications
- Company Website
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomarin Pharmaceutical Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 1999-07-23 | President, CEO & Director Mr. Alexander Hardy | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3040 | Website https://www.biomarin.com |
Full time employees 3040 | Website https://www.biomarin.com | ||
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.